<SEC-DOCUMENT>0000885725-23-000051.txt : 20231122
<SEC-HEADER>0000885725-23-000051.hdr.sgml : 20231122
<ACCEPTANCE-DATETIME>20231122160401
ACCESSION NUMBER:		0000885725-23-000051
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20231116
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231122
DATE AS OF CHANGE:		20231122

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BOSTON SCIENTIFIC CORP
		CENTRAL INDEX KEY:			0000885725
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				042695240
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11083
		FILM NUMBER:		231433384

	BUSINESS ADDRESS:	
		STREET 1:		300 BOSTON SCIENTIFIC WAY
		CITY:			MARLBOROUGH
		STATE:			MA
		ZIP:			01752-1234
		BUSINESS PHONE:		508-683-4000

	MAIL ADDRESS:	
		STREET 1:		300 BOSTON SCIENTIFIC WAY
		CITY:			MARLBOROUGH
		STATE:			MA
		ZIP:			01752-1234
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bsx-20231116.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:accfbc9b-b6f9-42e2-86a3-003f44f15930,g:e3ca2334-d848-4fe8-9ce5-a9f46e6577dc,d:656e4eb55ce84de7b7ee2f5e10feecd5--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:bsx="http://www.bostonscientific.com/20231116" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bsx-20231116</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-24">0000885725</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-25">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bsx-20231116.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-16</xbrli:startDate><xbrli:endDate>2023-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-16</xbrli:startDate><xbrli:endDate>2023-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:SeniorNotedue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-16</xbrli:startDate><xbrli:endDate>2023-11-16</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i656e4eb55ce84de7b7ee2f5e10feecd5_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">_____________________________________________________________________</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) OF THE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">_____________________________________________________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November 16, 2023</ix:nonNumeric></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">BOSTON SCIENTIFIC CORPORATION</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"></td><td style="width:31.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.073%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">1-11083</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">04-2695240</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">300 Boston Scientific Way</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Marlborough</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Massachusetts</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;              </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">01752-1234</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(Address of principal executive offices)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;             &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;   &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;  (Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">508</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">683-4000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant's telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:1.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.817%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:34.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.479%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-18">Common Stock, $0.01 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-19">BSX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-21">0.625% Senior Notes due 2027</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-22">BSX27</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-23">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i656e4eb55ce84de7b7ee2f5e10feecd5_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Departure of Directors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 16, 2023, Nelda J. Connors informed Boston Scientific Corporation (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) that she will not stand for re-election at the Company&#8217;s 2024 Annual Meeting of Stockholders (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2024 Annual Meeting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Ms. Connors has served as a member of the Board of Directors (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Board</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of the Company since December 2009 and currently serves as the chair of the Risk Committee and a member of the Executive Compensation and Human Resources Committee (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation Committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Ms. Connors will continue to serve as a director and in her committee roles until the 2024 Annual Meeting. Ms. Connors&#8217; decision not to stand for re-election at the 2024 Annual Meeting is not the result of any disagreement with the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 16, 2023, David J. Roux informed the Company that he will not stand for re-election at the Company&#8217;s 2024 Annual Meeting. Mr. Roux has served as a member of the Board since January 2014 and is currently a member of the Audit Committee and the Nominating and Governance Committee. Mr. Roux will continue to serve as a director and in his committee roles until the 2024 Annual Meeting. Mr. Roux&#8217;s decision not to stand for re-election at the 2024 Annual Meeting is not the result of any disagreement with the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board and Nominating and Governance Committee regularly review the size and composition of the Board and will continue to evaluate whether adding directors to the Board given Ms. Connors&#8217; and Mr. Roux&#8217;s departures is in the best interest of the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensatory Arrangements of Certain Officers</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.941%"><tr><td style="width:1.0%"></td><td style="width:29.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.357%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(i)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2024 Annual Bonus Plan</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2023, upon the recommendation of the Compensation Committee, the Board approved the Company&#8217;s 2024 Annual Bonus Plan effective for the performance period January 1, 2024 through December 31, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Company&#8217;s overall compensation program, the 2024 Annual Bonus Plan provides an annual cash incentive opportunity for eligible exempt and nonexempt indirect labor or equivalent personnel (including the Company&#8217;s named executive officers meeting the eligibility criteria) based on the achievement of certain performance metrics. The 2024 Annual Bonus Plan provides:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for a single bonus pool (the &#8220;Total Annual Bonus&#8221;) that will be based on the Company&#8217;s performance measured against achievement of corporate-level performance goals for global sales, adjusted earnings per share, and operating income (as a percent of sales), each as defined in the annual bonus plan, and attainment of quality and environmental, social, and governance (ESG) Scorecard goals;</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:6.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.705%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a ceiling of 150% of the aggregate Target Annual Bonus, as defined in the annual bonus plan, with the Board having discretion to terminate, suspend or modify the plan and to reduce the Total Annual Bonus based on the Company&#8217;s performance relative to its quality objectives and performance of its quality systems;</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:6.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">an allocation of the Total Annual Bonus among corporate, global supply chain and each participating business, and region (each, a &#8220;participating unit&#8221;). For corporate and global supply chain funding units (other than manufacturing plants), funding will track to the Total Annual Bonus pool funding, within a range of 10% in either direction, depending on the CEO&#8217;s assessment of the participating unit&#8217;s performance. For businesses, regions, and manufacturing plants, funding will be based on each participating unit&#8217;s overall and relative performance measured against its achievement of that unit&#8217;s predetermined &#8220;Scorecard&#8221; performance metrics and goals and taking into consideration, as appropriate, other factors; such allocation will be a percentage of the annual bonus pool target for each participating unit (representing the total target annual bonuses of all eligible employees for the year within that unit) (each such allocated amount, an &#8220;Assigned Bonus Pool&#8221;); and</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:6.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">an allocation of the Assigned Bonus Pool for each participating unit among all managers of plan participants within that participating unit. Such managers will then evaluate the performance of the participants under their management and determine, for each participant, the percentage (between 0% and 150%) of the participant&#8217;s target annual bonus that will be used to determine the participant&#8217;s bonus award.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards to certain executive officers under the 2024 Annual Bonus Plan are subject to (i) the Company&#8217;s discretionary recoupment policy, which provides that, to the extent permitted by law, the Company may seek reimbursement of a bonus award in the event of an executive officer&#8217;s misconduct or gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company and (ii) the Company&#8217;s Dodd-Frank Clawback Policy and any other compensation recovery policy adopted by the Board including in response to the requirements of Section 10D of the Securities Exchange Act of 1934, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the final rules of the U.S. Securities and Exchange Commission (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SEC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) thereunder, and any applicable listing rules or other rules and regulations implementing the foregoing or as otherwise required by law. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This description of the 2024 Annual Bonus Plan does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of such plan. A copy of the 2024 Annual Bonus Plan is included in this filing as Exhibit 10.1 and incorporated herein by reference.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.883%"><tr><td style="width:1.0%"></td><td style="width:22.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.122%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(ii)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2024 Performance Share Programs</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2023, upon the recommendation of the Compensation Committee, the Board approved the adoption of two performance share programs, the Company&#8217;s 2024 Relative Total Shareholder Return Performance Share Program (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2024 rTSR PSP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and 2024 Organic Net Sales Growth Performance Share Program (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2024 Organic Net Sales PSP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The 2024 rTSR PSP and the 2024 Organic Net Sales PSP are substantially similar to the 2023 Total Shareholder Return Performance Share Program and the 2023 Organic Net Sales Growth Performance Share Program, respectively. These programs represent an important component of the overall mix of the Company&#8217;s long-term incentive program. Under both programs, if the relevant program criteria are met, performance share awards will be granted to the Company&#8217;s executive officers in the form of restricted stock units issued under the Company&#8217;s Amended and Restated 2011 Long-Term Incentive Plan, which was amended and restated effective as of October 1, 2020 and previously approved by the Company&#8217;s stockholders. Awards to certain executive officers under both programs are subject to (i) the Company&#8217;s discretionary recoupment policy, which provides that, to the extent permitted by law, the Company may seek recovery of performance share units in the event of an executive officer&#8217;s misconduct or gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company and (ii) the Company&#8217;s Dodd-Frank Clawback Policy and any other compensation recovery policy adopted by the Board including in response to the requirements of Section 10D of the Exchange Act, the final rules of the SEC thereunder, and any applicable listing rules or other rules and regulations implementing the foregoing or as otherwise required by law.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.421%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(A)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2024 Relative Total Shareholder Return Performance Share Program</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the 2024 rTSR PSP is to align the Company&#8217;s executive compensation program with the interests of stockholders and to reinforce the concept of pay for performance by comparing the Total Shareholder Return (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">TSR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of the Company&#8217;s common stock to the TSR of the other companies included in the S&amp;P 500 Healthcare Index over a three-year period beginning on January 1, 2024 and ending on December 31, 2026. The number of performance shares awarded will be in a range of 0% to 200% of each participant&#8217;s target number of awards based on the Company&#8217;s TSR rank. Performance share awards will vest only upon satisfaction of both the performance criteria and the payment eligibility criteria set forth in the 2024 rTSR PSP, subject to certain exceptions in the event of a change of control or termination for retirement, death or disability. In the event a participant&#8217;s employment with the Company terminates due to retirement, as defined therein, prior to January 1, 2025, the performance share awards will be forfeited in their entirety.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This description of the 2024 rTSR PSP does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of such program. A copy of the 2024 rTSR PSP is included in this filing as Exhibit 10.2 and incorporated herein by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     (B)       2024 Organic Net Sales Growth Performance Share Program</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the 2024 Organic Net Sales PSP is to align the Company&#8217;s executive compensation program with the interests of stockholders and to reinforce the concept of pay for performance by providing incentives for the achievement of key business performance objectives critical to the Company&#8217;s success. Under the 2024 Organic Net Sales PSP, performance will be measured by comparing the Company&#8217;s organic net sales growth for the three-year period beginning on January 1, 2024 and ending on December 31, 2026 against its financial plan performance for organic net sales, as defined by the 2024 Organic Net Sales PSP. Organic net sales growth, as defined under the 2024 Organic Net Sales PSP, is net sales excluding the impact of foreign currency fluctuation and the impact of acquisitions and divestitures for which there are less than a full period of comparable net sales. The number of performance shares awarded will be in a range of 0% to 200% of each participant&#8217;s target number of awards, depending on such performance. Performance share awards will only vest upon satisfaction of both the performance criteria and the payment eligibility criteria set forth in the 2024 Organic Net Sales PSP, subject to certain exceptions in the event of a change of control or termination for retirement, death or disability. In the event a participant&#8217;s employment with the Company terminates due to retirement, as defined therein, prior to January 1, 2025, the performance share awards will be forfeited in their entirety.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This description of the 2024 Organic Net Sales PSP does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of such program. A copy of the 2024 Organic Net Sales PSP is included in this filing as Exhibit 10.3 and incorporated herein by reference.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9.01.          FINANCIAL STATEMENTS AND EXHIBITS.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;Exhibits</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 73pt;text-align:left;text-indent:-72pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101bostonscientific.htm">Boston Scientific Corporation 2024 Annual Bonus Plan, effective as of January 1, 2024</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 73pt;text-align:left;text-indent:-72pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102bostonscientific.htm">Boston Scientific Corporation 2024 Relative Total Shareholder Return Performance Share Program</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 73pt;text-align:left;text-indent:-72pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit103bostonscientific.htm">Boston Scientific Corporation 2024 Organic Net Sales Performance Share Program</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 73pt;text-align:left;text-indent:-72pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Documents filed or furnished with this report.</span></td></tr></table></div><div><span><br/></span></div><div id="i656e4eb55ce84de7b7ee2f5e10feecd5_10"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 22, 2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BOSTON SCIENTIFIC CORPORATION</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Susan Thompson</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Susan Thompson</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Chief Corporate Counsel and Assistant Secretary</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101bostonscientific.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib919fefb04fa4250a67cf2d099b2d9cd_1"></div><div style="min-height:143.28pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:52px;margin-bottom:5pt;vertical-align:text-bottom;width:146px"></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 Boston Scientific Annual Bonus Plan </font></div><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Period January 1 - December 31</font></div><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Version&#58; November 2023</font></div></td></tr></table></div><div style="padding-left:324pt;text-align:right"><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:29.34pt">Establishment and Purpose of the Plan</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Boston Scientific Corporation has established the Boston Scientific Corporation Annual Bonus Plan (&#34;Plan&#34;).   As explained in detail below, the Plan basically works as follows. For each Performance Year, there is an Aggregate Bonus Pool, which is the sum of the bonus targets of all eligible participants.  After the end of the Performance Year, the Committee determines the percentage of the pool that will be paid out as bonus for the year, based on the Company&#8217;s performance as to Global Sales, Adjusted Earnings Per Share, Operating Income (as a percent of sales), and its attainment of quality and Environmental, Social, and Governance (ESG) Scorecard goals.  The percentage will be between 0% and 150%. The payable portion of the pool is then separated into an Assigned Bonus Pool for each Business Group, Region and Unit, based on their performance as to their respective Scorecards.  The Compensation Management System then allocates the Assigned Bonus Pools among the managers, who evaluate the performance of the participants under their management and determine, for each participant, the percentage (between 0% and 150%) of the participant&#8217;s Target Annual Bonus that will be the participant&#8217;s Bonus Award for the Performance Year. </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Plan's purpose is to align the Company's interests and your interests as a Plan participant by providing incentive compensation for the achievement of Company and individual performance objectives.  </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The capitalized words and terms that are used throughout the Plan are defined in the Glossary in Article IX.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.01pt">Eligibility and Participation</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You are eligible to participate in the Plan for a Performance Year if you satisfy all of the following eligibility criteria&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">You are either a Regular Employee or an Eligible International Employee&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">You are not eligible for commissions under any sales compensation plan of the Company (unless the written terms of the plan or program expressly permit participation in both that plan or program and the Plan)&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">You are not eligible to participate in any other incentive plan or program of the Company (unless the written terms of that plan or program expressly permit participation in both that plan or program and the Plan)&#59; and</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">You complete at least two full months of Eligible Service during the Performance Year.  </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For Exempt Employees and Eligible International Employees, if you are eligible to participate in the Plan for only part of the Performance Year (for example, because you change positions or business units during the Performance Year), then you may participate in the Plan on a prorated basis for the Performance Year, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided that</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> you complete at least two full months of Eligible Service during the Performance Year.  If you are eligible for prorated participation, the Bonus Award, if any, otherwise payable to you for the Performance Year will be prorated based on your percentage of time in an eligible position during the Performance Year.  This paragraph does not apply to Non-Exempt Employees.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.68pt">Target Annual Bonus</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exempt Employees and Eligible International Employees&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> For each Performance Year in which you are eligible to participate, you will be assigned a Target Annual Bonus, which will be a specified percentage of your annual base salary, determined based on your position.  The Bonus Award, if any, that you ultimately receive for the Performance Year will be a percentage of your Target Annual Bonus, determined pursuant to Article IV. The Aggregate Bonus Pool for a Performance Year will be the sum of the Target Annual Bonuses of all employees who are eligible to participate in the Plan for the Performance Year. All Bonus Awards will be based on your annual base salary and incentive target as of December 31 of the Performance Year.  </font></div><div><font><br></font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:143.28pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:52px;margin-bottom:5pt;vertical-align:text-bottom;width:146px"></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 Boston Scientific Annual Bonus Plan </font></div><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Period January 1 - December 31</font></div><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Version&#58; November 2023</font></div></td></tr></table></div><div style="padding-left:324pt;text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-exempt employees&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  For each Performance Year in which you are eligible to participate, you will be assigned a Target Annual Bonus, which will be a specified percentage of your total annual earnings including only regular pay, shift differentials and overtime earnings, determined based on your position.  The Bonus Award, if any, that you ultimately receive for the Performance Year will be a percentage of your Target Annual Bonus, determined pursuant to Article IV. The Aggregate Bonus Pool for a Performance Year will be the sum of the Target Annual Bonuses of all employees who are eligible to participate in the Plan for the Performance Year. All Bonus Awards will be based on your annual earnings and incentive target as of December 31 of the Performance Year.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IV.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.34pt">Steps For Determining Bonus Awards</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonus Awards for a Performance Year will be determined pursuant to the following steps&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Step One&#58; Establish performance goals and the Corporate Performance Scale</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On or before March 15 of a Performance Year, the Committee will establish performance goals for each of the Plan's Performance Metrics quality and ESG goals for the Performance Year.  The Performance Metrics are Global Sales, Adjusted Earnings Per Share and Operating Income (as a percent of Sales).  The Committee will also approve the Corporate Performance Scale for the Performance Year, which will be set forth in a separate schedule.    </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Step Two&#58;  Measure achievement and determine Total Annual Bonus </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After the end of the Performance Year, the Committee will evaluate the Company's financial performance results for the Performance Year and determine the extent to which the performance goals were attained.  The Committee will adopt a written resolution as to the extent of the attainment of the performance goals with respect to each of the Performance Metrics.  Based on the extent to which the performance goals were attained, the Chief Executive Officer will make a recommendation to the Committee, consistent with the Corporate Performance Scale, as to the Applicable Percentage of the Aggregate Bonus Pool to be paid by the Company as the Total Annual Bonus for the Performance Year.  Taking into account the Chief Executive Officer's recommendation and any other factors that the Committee, in its discretion, deems appropriate, the Committee will approve an Applicable Percentage for the Performance Year, which must be consistent with the Corporate Performance Scale.  The Committee retains the right to reduce the Total Annual Bonus for the Performance Year based on the Committee's Quality Assessment.      </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Step Three&#58; Allocate the Total Annual Bonus</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Chief Executive Officer will make a recommendation to the Committee as to how the Total Annual Bonus for the Performance Year should be allocated among the Business Groups and Regions, based on their overall and relative performance against their respective applicable Scorecards for the Performance Year.  Taking into account the Chief Executive Officer's recommendation and any other factors that the Committee, in its discretion, deems appropriate, the Committee will approve an allocation of the Total Annual Bonus among the Business Groups and Regions for the Performance Year.  The portion of the Total Annual Bonus allocated to a Business Group or Region (its Assigned Bonus Pool) will be a percentage of the total Target Annual Bonuses of all its employees who participate in the Plan for the Performance Year.  If a Business Group or Region has Units, the leader of the Business Group or Region will divide the Assigned Bonus Pool among the Units, based on their overall and relative performance against each Unit's applicable Scorecard for the Performance Year, so that each Unit will then have its own Assigned Bonus Pool.  A Business Group or Region that does not have Units (for example, Corporate) will have a single Assigned Bonus Pool.  </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Step Four&#58; Determine participants' individual Bonus Awards</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Once the Assigned Bonus Pool is determined for each Business Group, Region, or Unit, the amount of the Assigned Bonus Pool will be entered into the Compensation Management System, which allocates a portion of the Assigned Bonus Pool to each manager of Plan participants.  Each manager will evaluate the performance of each participant under his or her management and </font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:143.28pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:52px;margin-bottom:5pt;vertical-align:text-bottom;width:146px"></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 Boston Scientific Annual Bonus Plan </font></div><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Period January 1 - December 31</font></div><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Version&#58; November 2023</font></div></td></tr></table></div><div style="padding-left:324pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">enter into the Compensation Management System a rating percentage, from 0% to 150%, for each evaluated participant.  The rating percentage that your manager assigns to you will, in turn, determine the percentage of your Target Annual Bonus that will be your Bonus Award for the Performance Year.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If participants leave the Company before the Payment Date and, as a result, do not earn their Bonus Awards for the Performance Year, their Bonus Awards will be reallocated by the Chief Executive Officer, in his or her discretion, to other participants who are employed on the Payment Date and will become part of the Bonus Awards paid to those other participants.  As provided in Article V, all Bonus Awards for a Performance Year (including those reallocated pursuant to the previous sentence) will be paid to eligible participants no later than March 15 of the following year.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">V.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.67pt">Payment Conditions</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Payment Date and Form of Payment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Bonus Awards in the United States will be made by March&#160;15 of the year following the Performance Year for which the Bonus Awards are made. Bonus Awards outside the United States will be processed as soon as administratively possible in each region following the end of the Performance Year and after the Committee has adopted its written resolution as to the attainment of performance goals pursuant to Article IV.  Your Bonus Award, if any, will be paid in a single lump sum payment.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Required Employment on the Payment Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Except as otherwise expressly provided in this Article V, to be eligible to receive payment of any Bonus Award, you must be employed by the Company on the Payment Date for that Bonus Award.  In other words, except as expressly provided in this Article V, if you cease employment with Boston Scientific Corporation and all of its Affiliates before the Payment Date, you will not be eligible to receive any Bonus Award that would otherwise have been payable to you if you had been a Company employee on that date.  Conversely, if you are an employee of the Company on the Payment Date, you will be entitled to your Bonus Award, if any, even if you are not actively performing duties on that date.  For example, if you are not required to report to work during a notification period applicable under a Company severance or separation plan, but you are still a Company employee during that period, and the Payment Date occurs during your notification period, you will remain eligible to receive your Bonus Award.  </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exception Under Written Company Plan or Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If you are specifically exempted, under a written Company plan or agreement, from the requirement to be employed on the Payment Date, you may remain eligible for payment of your Bonus Award, depending on the terms of the applicable written plan or agreement.  In such cases, the terms of such written plan or agreement will govern in all respects.      </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Layoff</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Also, notwithstanding any other provision of the Plan, if you are a participant and your employment ceases prior to the Payment Date by reason of Layoff, you may be eligible for payment of part or all of your Bonus Award, depending on the terms and conditions of the applicable severance pay plan, if any, for the country in which you are employed at the time of layoff. In the event that there is no country-specific severance plan for the country in which you are employed at the time of your Layoff, applicable law will apply.  In the event a previously eligible participant is re-hired within the Performance Year after a layoff and meets the eligibility criteria, if the participant was paid out a pro-rated bonus at the time of severance, then the payout period will not be bridged. If the rehired participant did not receive a pro-rated bonus payout at the time of severance, then the payout period will be bridged, and participant will receive a pro-rated Bonus Award for the Performance Year. </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Also, notwithstanding any other provision of the Plan, if you are a participant on a paid leave of absence, you are bonus eligible as long as you meet performance expectations during the Performance Year. Your Bonus Award will be made on the payment date within the applicable country. If you are a participant on an unpaid leave of absence, your Bonus Award, if any, will be pro-rated if the unpaid leave is longer than a continuous six (6) months in </font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:143.28pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:52px;margin-bottom:5pt;vertical-align:text-bottom;width:146px"></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 Boston Scientific Annual Bonus Plan </font></div><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Period January 1 - December 31</font></div><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Version&#58; November 2023</font></div></td></tr></table></div><div style="padding-left:324pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">duration during the Performance Year. Country specific regulations regarding leaves of absence and bonus eligibility supersede this Plan document.     </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Also notwithstanding any other provision of the Plan, if you are a participant for a Performance Year and your employment ceases due to Retirement prior to the Payment Date for a Bonus Award but after September 30 of the Performance Year to which the Bonus Award pertains, and you had at least nine months of Eligible Service in the Performance Year, you will be entitled to a prorated portion of the Bonus Award, if any, that would otherwise be paid you for the Performance Year. In such a case, proration will be based on the percentage of time in the Performance Year during which you were employed and eligible to participate in the Plan.  The prorated Bonus Award, if any, will be paid on the Payment Date.  For purposes of this paragraph, your employment ceases due to &#8220;Retirement&#8221; if, as of the date of your cessation of employment, (1) you had attained age 55, (2) you had accrued at least five years of service with the Company and (3) the sum of your age and years of service as of your date of cessation of employment equals or exceeds 65.  </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Death</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  For Exempt Employees and Eligible International Employees, if your employment ceases prior to the Payment Date by reason of your death, but you otherwise met all eligibility criteria specified in Article II, your estate may receive a prorated portion of the Bonus Award, if any, that would have been paid had you lived to the Payment Date.  In such a case, proration will be based on the percentage of time in the Performance Year during which you were employed and eligible to participate in the Plan.  The prorated Bonus Award, if any, will be paid on the Payment Date.  </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For Non-Exempt employees, if your employment ceases prior to the Payment Date by reason of your death, but you otherwise met all eligibility criteria specified in Article II, your estate will receive your Bonus Award, if any, that would have been paid had you lived to the Payment Date.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Adjustment for Changes in Standard Hours</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Also notwithstanding any other provision of the Plan, if you are an Exempt Employee or Eligible International employee participant and have a change in standard hours (part-time to full-time, full-time to part-time) during a Performance Year, your Bonus Award, if any, for the Performance Year will be calculated as follows&#58;  Target Annual Bonus percentage multiplied by the average annualized base salary for each period of employment at a specific salary divided by the percentage of the year during which that salary was earned.  For example, if your Target Annual Bonus percentage is 10% and you worked full-time for six (6) months at an annual base salary of 100,000 and moved to a part-time arrangement for the remaining (6) months at an annual base salary of 50,000, your bonus award, if any, would be 7,500.  &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">0.10 x (100,000 x 0.50) &#61; 5,000&#93; and &#91;0.10 x (50,000 x 0.50) &#61; 2,500&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  This paragraph does not apply to Non-Exempt Employee participants.  </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">No Guarantee of a Bonus Award</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Nothing in this Plan guarantees that any Bonus Award will be made to any individual.  Receipt of a Bonus Award in one year does not guarantee eligibility in any future year.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font><br></font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VI.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.34pt">Incentive Compensation Recoupment Policy</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">General Recoupment Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  To the extent permitted by governing law, the Board, in its discretion, may seek reimbursement of a Bonus Award paid to you if you are a Current Executive Committee Member or Former Executive Committee Member and, in the judgment of the Board, you, while serving in capacity as a Current Executive Committee Member, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company.  Further, in such case&#58;</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">if you are a Current Executive Committee Member, the Board may seek reimbursement of all or a portion of the Bonus Award paid to you during the one-year period preceding the date on which such misconduct or dereliction of duty was discovered by the Company, or</font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:143.28pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:52px;margin-bottom:5pt;vertical-align:text-bottom;width:146px"></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 Boston Scientific Annual Bonus Plan </font></div><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Period January 1 - December 31</font></div><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Version&#58; November 2023</font></div></td></tr></table></div><div style="padding-left:324pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">if you are a Former Executive Committee Member, the Board may seek reimbursement of all or a portion of the Bonus Award paid to you during the one-year period preceding the last date on which you were a Current Executive Committee Member. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Recoupment Required by Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Bonus Awards and any compensation associated therewith are subject to forfeiture, recovery by the Company or other action pursuant to any compensation recovery policy adopted by the Board or the Committee in effect from time to time, which includes but is not limited to the Company&#8217;s Dodd-Frank Clawback Policy and any other compensation recovery policy adopted by the Board or the Committee including in response to the requirements of Section 10D of the Securities Exchange Act of 1934, as amended, the U.S. Securities and Exchange Commission&#8217;s final rules thereunder, and any applicable listing rules or other rules and regulations implementing the foregoing or as otherwise required by law.   </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VII.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.01pt">Termination, Suspension or Modification and Interpretation of the Plan</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Board may terminate, suspend or modify (and if suspended, may reinstate with or without modification) all or part of the Plan at any time, with or without notice to participants.  The Committee has sole authority over administration and interpretation of the Plan, and the Committee retains its right to exercise discretion as it sees fit. </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Committee reserves the exclusive right to determine eligibility to participate in this Plan and to interpret all applicable terms and conditions, including eligibility criteria, performance objectives and payment conditions, for the Company's executive officers.  The Committee delegates to the Company&#8217;s highest human resources officer the authority to administer, and determine eligibility to participate in, the Plan and interpret all applicable terms and conditions, for employees who are not executive officers of the Company.  The determinations and interpretations of the Committee and its delegates will be conclusive.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Bonus Awards are paid from the Company's general assets.  No trust, account or other separate collection of amounts will be established for the payment of Bonus Awards under the Plan.  Bonus Awards are unfunded obligations of the Company, so if and when a Bonus Award becomes due, a participant's rights to payment are no greater than the rights of a general unsecured creditor.  </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIII.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:14.68pt">Other</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This document sets forth the terms of the Plan and is not intended to be a contract or employment agreement between you or any other participant and the Company.  As applicable, it is understood that both you and the Company have the right to terminate your employment with the Company at any time, with or without cause and with or without notice, in acknowledgement of the fact that your employment relationship with the Company is &#8220;at will.&#8221;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IX.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.34pt">Glossary</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As used in the Plan, the following words and terms, when capitalized, have the following meanings&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Adjusted Earnings Per Share</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means, with respect to a Performance Year, Adjusted Net Income (loss) divided by weighted average shares outstanding for the Performance Year (determined in accordance with generally accepted accounting principles).</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Adjusted Net Income (loss)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> equals the Company's GAAP Net Income (loss)  excluding certain charges (credits) from GAAP net income, including, but not limited to, amortization expense, goodwill and intangible asset impairment charges, acquisition- and divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), litigation-related net charges (credits), certain investment impairment losses (gains), EU Medical Device Regulation implementation charges, pension termination charges, debt extinguishment charges and discrete tax items.</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:143.28pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:52px;margin-bottom:5pt;vertical-align:text-bottom;width:146px"></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 Boston Scientific Annual Bonus Plan </font></div><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Period January 1 - December 31</font></div><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Version&#58; November 2023</font></div></td></tr></table></div><div style="padding-left:324pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means any corporation, trust, partnership, or any other entity that is considered to be a single employer with Boston Scientific Corporation under Code sections 414(b), (c), (m), or (o), such as a wholly-owned (or at least 80%-owned) subsidiary of Boston Scientific Corporation.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Aggregate Bonus Pool</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means, with respect to a Performance Year, the sum of the Target Annual Bonuses of all employees who are eligible to participate in the Plan for the Performance Year.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Applicable Percentage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means, with respect to a Performance Year, a percentage, determined by the Committee in accordance with the Corporate Performance Scale, which is between 0% and no more than 150%.  The Applicable Percentage is used to determine the portion of the Aggregate Bonus Pool that the Company will pay out as the Total Annual Bonus for the Performance Year.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assigned Bonus Pool</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means, with respect to a Business Group, Region, or Unit for a Performance Year, the portion of the Total Annual Bonus assigned to the Business Group, Region, or Unit to be paid as Bonus Awards for the Performance Year to eligible participants who worked for the Business Group, Region, or Unit during the Performance Year.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the Board of Directors of Boston Scientific Corporation.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Bonus Award</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means, with respect to a participant for a Performance Year, the annual incentive bonus, if any, payable to the participant for the Performance Year, subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Business Group</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means a functional or product-based area of the Company's business, as designated by the Chief Executive Officer from time to time. </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Chief Executive Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the Chief Executive Officer of Boston Scientific Corporation.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the Internal Revenue Code of 1986, as amended, and its interpretive rules and regulations.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the Executive Compensation and Human Resources Committee of the Board.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means Boston Scientific Corporation and its Affiliates.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation Management System</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the software tool used by the Company for various compensation management purposes.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Corporate Performance Scale</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means, with respect to a Performance Year, the schedule used to determine, based on the extent of attainment of the performance goals for the Performance Year, the Applicable Percentage of the Aggregate Bonus Pool to be paid as the Total Annual Bonus for the Performance Year.  The Corporate Performance Scale must provide that the Applicable Percentage for a Performance Year cannot be less than 50%.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Current Executive </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Committee Member means any individual  currently designated as a corporate officer of the Company who is in an organizational job level of E-4 or E-5 (or any equivalent level under any future organizational framework).</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Eligible International Employee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means an international, international operations, or expatriate employee of the Company working in a position designated by the Company as eligible to participate in the Plan.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Eligible Service</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means periods in which you are considered, under the rules and procedures of the Company, to be in active service as a Regular Employee or Eligible International Employee (including, but not limited to, time away from work for approved vacation, recognized holidays, and FMLA leave).</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Environmental, Social and Governance (ESG) Scorecard means</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, with respect to a Performance Year, performance against global gender and US (inclusive of Puerto Rico) multicultural goals, Engagement goals, and performance against annual environmental goals that are aligned with the Company&#8217;s environmental strat plan goals.</font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:143.28pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:52px;margin-bottom:5pt;vertical-align:text-bottom;width:146px"></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 Boston Scientific Annual Bonus Plan </font></div><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Period January 1 - December 31</font></div><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Version&#58; November 2023</font></div></td></tr></table></div><div style="padding-left:324pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Executive </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Committee Member means any Current Executive Committee Member or Former Executive Committee Member.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exempt Employee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means an employee of the Company who is on the Company's United States payroll and (1) classified by the Company as a regular full-time or regular part-time Employee&#59; (2) performs a job that the Company has determined to be exempt from the minimum wage and overtime requirements of the Fair Labor Standards Act of 1938, as amended (FLSA)&#59; and (3) is </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> any of the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">classified by the Company as an intern, summer student, co-op employee, or similar short-term employee&#59; or</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">classified by the Company as a consultant, temporary or defined-term employee (such as temporary fellowship program employees), or similar category of limited-term employment, regardless of their work schedule or number of hours worked.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Former Executive </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Committee Member means any individual previously (but not currently) designated as a corporate officer of the Company who was in an organizational job level of E-4 or E-5 (or any equivalent level under any future organizational framework).</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Global Sales</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> for purposes of the Annual Bonus Plan measures sales using constant currency rates and excludes acquisitions and divestitures not included in the annual operating plan.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Layoff</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means a layoff or similar involuntary termination from employment that renders you eligible for severance pay under a Company severance plan or applicable law.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Exempt Employee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means an employee of the Company who is on the Company's United States payroll and (1) classified by the Company as a regular full-time or regular part-time Employee&#59; and (2) performs a job that the Company has determined to be non-exempt from the minimum wage and overtime requirements of the Fair Labor Standards Act of 1938, as amended (FLSA).</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Operating Income (as a percent of Sales) means</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> the company&#8217;s revenue less cost of goods sold less operating expenses, adjusted for certain items consistent with those used to determine the company&#8217;s adjusted earnings per share. These adjustment items include amortization expense, goodwill and other intangible asset impairments, acquisition&#47;divestiture-related net charges (credits), restructuring and restructuring-related net credits, certain litigation-related net charges (credits), and EU MDR implementation costs.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Payment Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means, with respect to a Performance Year, the date on which Bonus Awards for the Performance Year are paid to participants, which will be no later than March 15 of the following year.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Metrics</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means Global Sales, Adjusted Earnings Per Share, and Operating Income (as a percent of Sales).</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Year</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> for all metrics except environmental metrics, means the 12-month period beginning on January 1 and ending on the following December 31. For the environmental metrics, the 12-month period beginning October 1, 2023 and ending on the following September 30, 2024.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the Boston Scientific Annual Bonus Plan, which is set forth in this document, as it may be amended from time to time.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Quality Assessment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the process undertaken by the Committee following the end of each Performance Year, to evaluate the Company's progress made toward achievement of&#160;its quality objectives and the performance of the Company-wide quality system.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Region</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means a geographic region, as designated by the Chief Executive Officer from time to time, comprising a portion of the Company's international business.  </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Regular Employee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means an employee of the Company who is on the Company's United States payroll and is considered an Exempt Employee or Non-Exempt Employee. </font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:143.28pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:52px;margin-bottom:5pt;vertical-align:text-bottom;width:146px"></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 Boston Scientific Annual Bonus Plan </font></div><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Period January 1 - December 31</font></div><div style="padding-left:91.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Version&#58; November 2023</font></div></td></tr></table></div><div style="padding-left:324pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Retirement has the meaning given in Section V in the paragraph entitled &#8220;Retirement.&#8221;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Scorecard</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means, with respect to a Performance Year, the tool used to establish performance measures and objectives with respect to a Business Group, Region, or Unit for the Performance Year. </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Target Annual Bonus</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> has the meaning given to that term in Article III.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Total Annual Bonus</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> represents, with respect to a Performance Year, the total dollars to be paid out by the Company to all participating employees as Bonus Awards for the Performance Year.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Unit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means a business unit of Business Group or Region, such as a plant or division (for a Business Group) or a country or group of countries (for a Region)&#59; the Units of a Business Group or Region may change from time to time.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;9</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit102bostonscientific.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="idbd8c606b5d5465f8e228d3a5ff05204_1"></div><div style="min-height:144pt;width:100%"><div style="padding-left:319.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div><div style="padding-left:319.5pt;text-align:right"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Relative Total Shareholder Return Performance Share Program (&#8220;rTSR Program&#8221;)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Period January 1, 2024 - December 31, 2026</font></div></td></tr></table></div><div><font><br></font></div></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:29.34pt">Purpose of the rTSR Program</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The purpose of the rTSR Program is to align Boston Scientific&#8217;s executive compensation program with the interests of shareholders and to reinforce the concept of pay for performance by comparing the Total Shareholder Return of shares of Boston Scientific Common Stock (the &#8220;Common Stock&#8221;) to the TSR of companies included in the S&#38;P 500 Healthcare Index over a three-year period beginning on January 1, 2024.  </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The rTSR Program entails the grant of Restricted Stock Units, and the program shall be administered, under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the &#8220;2011 LTIP&#8221;).  Terms not defined in this rTSR Program document but defined in the 2011 LTIP shall have the same meaning as in the 2011 LTIP.  </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.01pt">Eligible Participants</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The rTSR Program covers members of the Executive Committee on the date that awards are granted under the rTSR Program as determined and, in the amounts, established by the Executive Compensation and Human Resources Committee of the Board of Directors (the &#8220;Committee&#8221;).</font></div><div style="margin-bottom:8pt;margin-top:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">III.&#160;&#160;&#160;&#160;Performance Share Units </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Restricted Stock Units awarded under the rTSR Program (the &#8220;Performance Share Units&#8221;) shall vest only upon satisfaction of both the performance criteria described in this Section III and the payment eligibility criteria described in Section VII.  The applicable performance criteria are based on the TSR of the Common Stock relative to the TSR of companies in the S&#38;P 500 Healthcare Index.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The TSR for Boston Scientific and all other companies in the S&#38;P 500 Healthcare Index will be measured over a three-year period beginning January 1, 2024 and ending on December 31, 2026 (the &#8220;Performance Period&#8221;). </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The number of Performance Share Units as to which the performance criteria under this rTSR Program shall be determined to have been satisfied will be in a range of 0% to 200% of the target number of Performance Share Units awarded to the participant as follows&#58; </font></div><div style="padding-left:95.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.352%"><tr><td style="width:1.0%"></td><td style="width:48.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">rTSR Performance</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Percentile Rank</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 19pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Performance Share Units<br>as a Percent of Target</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75th Percentile or above</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55th Percentile</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25th Percentile</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below 25</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Percentile</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the minimum level of performance is achieved, the number of Performance Share Units will be calculated linearly between each set of data points. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Following the end of the Performance Period, the Committee shall determine the number of Performance Share Units as to which the performance criteria of this program have been satisfied, which determination shall be final and binding. Shares of Common Stock will be delivered or otherwise made available to the participant no later than March 15, 2027 in settlement of the Performance Share Units as to which the performance criteria of this program </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:144pt;width:100%"><div style="padding-left:319.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div><div style="padding-left:319.5pt;text-align:right"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Relative Total Shareholder Return Performance Share Program (&#8220;rTSR Program&#8221;)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Period January 1, 2024 - December 31, 2026</font></div></td></tr></table></div><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">have been satisfied if and to the extent the payment eligibility criteria of Section VII below are also satisfied.  Any Performance Share Units as to which the performance criteria of this Section III have not been satisfied will be forfeited in their entirety.</font></div><div><font><br></font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IV. &#160;&#160;&#160;&#160;Calculation of Total Shareholder Return and Definitions</font></div><div><font><br></font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The TSR for Boston Scientific and each other company in the S&#38;P 500 Healthcare Index shall include any cash dividends paid during the Performance Period and shall be determined as follows&#58;</font></div><div style="margin-top:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Shareholder Return for the Performance Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#61; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Change in Stock Price + Dividends Paid) &#47; Beginning Stock Price</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the daily average closing price as quoted on the New York Stock Exchange or the NASDAQ Global Select Market, as applicable, of one (1) share of common stock for the two calendar months </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">prior</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> to the beginning of the Performance Period. </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the difference between the Beginning Stock Price and the Ending Stock Price.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dividends Paid</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the total of all cash dividends paid on one (1) share of stock during the Performance Period.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the daily average closing price as quoted on the New York Stock Exchange or the NASDAQ Global Select Market, as applicable, of one (1) share of common stock for the last two calendar months of the Performance Period.</font></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Example&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the Beginning Stock Price for a company was $25.00 per share, and the company paid $2.50 in dividends over the Performance Period, and the Ending Stock Price was $30.00 per share (thereby making the Change in Stock Price $5.00 ($30.00 minus $25.00)), then the TSR for that company would be thirty percent (30%).  The calculation is as follows&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.30</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#61; ($5.00 + $2.50) &#47; $25.00</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">V. &#160;&#160;&#160;&#160;Calculation of Percentile Performance</font></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Following the calculation of the TSR for the Performance Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">for Boston Scientific and each of the other companies in the S&#38;P 500 Healthcare Index, Boston Scientific and the other companies in the S&#38;P 500 Healthcare Index will be ranked, in order of maximum to minimum, according to their respective TSR for the Performance Period.</font></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After this ranking, the percentile performance of Boston Scientific as compared to the other companies in the S&#38;P 500 Healthcare Index shall be determined by the following formula&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:56px;margin-bottom:5pt;vertical-align:text-bottom;width:139px"></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;P&#8221; represents the percentile performance which will be rounded, if necessary, to the nearest whole percentile by application of standard scientific rounding conventions. </font></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;N&#8221; represents the number of companies in the S&#38;P 500 Healthcare Index, including Boston Scientific.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:144pt;width:100%"><div style="padding-left:319.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div><div style="padding-left:319.5pt;text-align:right"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Relative Total Shareholder Return Performance Share Program (&#8220;rTSR Program&#8221;)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Period January 1, 2024 - December 31, 2026</font></div></td></tr></table></div><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;R&#8221; represents Boston Scientific&#8217;s ranking versus the other companies in the S&#38;P 500 Healthcare Index. </font></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Example&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If Boston Scientific ranked 10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> out of 54 companies, the performance (&#8220;P&#8221;) therefore will be in the 83</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> percentile.</font></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This calculation is as follows&#58;  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.83</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#61; 1 &#8211; (10 &#8211; 1) &#47; (54 &#8211; 1)</font></div><div><font><br></font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VI. &#160;&#160;&#160;&#160;S&#38;P 500 Healthcare Index </font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The companies currently included in the S&#38;P 500 Healthcare Index can be found in Appendix A attached hereto.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Only companies in the S&#38;P 500 Healthcare Index for an entire Performance Period will be used to determine the TSR percentile rank. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If two companies in the S&#38;P 500 Healthcare Index merge, the surviving company shall remain in the S&#38;P 500 Healthcare Index.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If a company in the S&#38;P 500 Healthcare Index merges with, or is acquired by, a company that is not in the S&#38;P 500 Healthcare Index, and the company in the S&#38;P 500 Healthcare Index is the surviving company, then the surviving company shall be included in the S&#38;P 500 Healthcare Index.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If a company in the S&#38;P 500 Healthcare Index merges with, or is acquired by, a company that is not in the S&#38;P 500 Healthcare Index, and the company in the S&#38;P 500 Healthcare Index is not the surviving company or the surviving company is no longer publicly traded, then the surviving company shall not be included in the S&#38;P 500 Healthcare Index.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if a company in the S&#38;P 500 Healthcare Index ceases to be listed in the Healthcare Sector under the Standard &#38; Poor&#8217;s Global Industry Classification Standard (GICS) at any time during the Performance Period (including after a merger, acquisition or other business transaction described above), then it shall not be included in the S&#38;P 500 Healthcare Index. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VII. &#160;&#160;&#160;&#160;Payment Eligibility Criteria</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Except as set forth below with respect to a Change in Control, no Performance Share Units shall vest prior to the end of the Performance Period (December 31, 2026). </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If a participant&#8217;s employment with Boston Scientific and its Affiliates (the &#8220;Company&#8221;) terminates before the last day of the Performance Period, all of his or her Performance Share Units shall be forfeited in their entirety except as set forth below.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participants on military, sick or other bona fide leave of absence on December 31, 2026 will not be deemed to have terminated employment with the Company if such absence does not exceed 180 days or, if longer, the period the participant retains the right by statute or by contract to return to employment with the Company. </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to the terms of any separate Change in Control or similar agreement to which a participant is bound, if there is a Change in Control after December 31, 2024 but before the end of the Performance Period, shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this program have been satisfied using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2026, as determined by the Committee immediately prior to the consummation of the Change in Control.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:144pt;width:100%"><div style="padding-left:319.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div><div style="padding-left:319.5pt;text-align:right"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Relative Total Shareholder Return Performance Share Program (&#8220;rTSR Program&#8221;)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Period January 1, 2024 - December 31, 2026</font></div></td></tr></table></div><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Such issuance shall occur within 70 days of the effective date of the Change in Control, on a prorated basis.  The number of shares to be issued on a prorated basis shall be determined as follows&#58; (# Performance Share Units achieved pursuant to the table in Section III * ((# of full and partial months during the Performance Period, rounded up to the nearest whole month&#47;36)).  The number of prorated shares to be issued to the participant, if any, will be approved by the Committee at its next regular meeting.  In the event a Change in Control occurs prior to January 1, 2025, the Performance Share Units will be forfeited in their entirety.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If a participant&#8217;s employment with the Company terminates due to Retirement after December 31, 2024 but before the end of the Performance Period, the participant will continue to be eligible to vest in a pro rated number of Performance Share Units and shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this program have been satisfied at the end of the Performance Period, but no later than March 15, 2027, on a prorated basis using the effective date of the participant&#8217;s termination of employment. The number of shares to be issued on a prorated basis shall be determined as follows&#58; (# Performance Share Units achieved pursuant to the table in Section III * ((# of full and partial months worked during the Performance Period, rounded up to nearest whole month) &#47; 36)).  The number of prorated shares, if any, to be issued to the participant will be approved by the Committee at its regular meeting next following the date of the participant&#8217;s employment termination. In the event a participant&#8217;s employment with the Company terminates due to Retirement prior to January 1, 2025, the Performance Share Units will be forfeited in their entirety.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If a participant&#8217;s employment with the Company terminates due to death or Disability before the end of the Performance Period, the participant will continue to be eligible to vest in all of his or her Performance Share Units and shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this program have been satisfied at the end of the Performance Period, but no later than March 15, 2027. The number of shares, if any, to be issued to the participant will be approved by the Committee at its regular meeting next following the date of the participant&#8217;s employment termination. </font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIII. &#160;&#160;&#160;&#160;Termination, Suspension or Modification and Interpretation of the rTSR </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Program</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Committee has sole authority over administration and interpretation of the rTSR Program.  The Committee hopes and expects to continue the program in effect but retains its right to exercise discretion as it sees fit, including to prospectively terminate, suspend or modify the rTSR program or criteria for eligible participation in future years.  If suspended, the Committee may reinstate with or without modification all or part of the rTSR Program or criteria for eligible participation&#59; However, no amendment of the Program after the grant date may materially and adversely impair a participant&#8217;s rights under awards made pursuant to the rTSR Program without the participant&#8217;s consent unless the amendment is necessary or desirable to facilitate compliance with applicable law, as determined in the sole discretion of the Committee.  The Committee reserves the exclusive right to determine eligibility to participate in this rTSR Program and to interpret all applicable terms and conditions.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IX. &#160;&#160;&#160;&#160;Recoupment Policy</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">General Recoupment Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  To the extent permitted by governing law, the Board, in its discretion, may seek Recovery of Performance Share Units granted to a Current Executive Committee Member or Former Executive Committee Member if, in the judgment of the Board, such Executive Committee Member, while serving in capacity as a Current Executive Committee Member, commits misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:144pt;width:100%"><div style="padding-left:319.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div><div style="padding-left:319.5pt;text-align:right"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Relative Total Shareholder Return Performance Share Program (&#8220;rTSR Program&#8221;)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Period January 1, 2024 - December 31, 2026</font></div></td></tr></table></div><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The following terms shall have the meaning set forth below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;&#34;Current Executive Committee Member&#34; means any individual currently designated as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">a corporate officer of the Company who is in an organizational job level of E-4 or E-5 (or any equivalent level under any future organizational framework)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;&#34;Executive Committee Member&#34; means any Current Executive Committee Member or Former Executive Committee Member.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-108pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;&#34;Former Executive Officer&#34; means any individual previously (but not currently) designated as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">a corporate officer of the Company who was in an organizational job level of E-4 or E-5 (or any equivalent level under any future organizational framework)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;&#34;Recovery&#34; means the forfeiture or cancellation of unvested Performance Share Units.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Recoupment Required by Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Performance Share Units and any compensation associated therewith are subject to forfeiture, recovery by the Company or other action pursuant to any compensation recovery policy adopted by the Board or the Committee in effect from time to time, which includes but is not limited to the Company&#8217;s Dodd-Frank Clawback Policy and any other compensation recovery policy adopted by the Board or the Committee including in response to the requirements of Section 10D of the Securities Exchange Act of 1934, as amended, the U.S. Securities and Exchange Commission&#8217;s final rules thereunder, and any applicable listing rules or other rules and regulations implementing the foregoing or as otherwise required by law. </font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">X. &#160;&#160;&#160;&#160;Other</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This document sets forth the terms of the rTSR Program and is not intended to be a contract or employment agreement between the participant and the Company.  As applicable, it is understood that both the participant and the Company have the right to terminate the participant&#8217;s employment with the Company at any time, with or without cause and with or without notice, in acknowledgement of the fact that their employment relationship is &#8220;at will.&#8221; </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To the extent section 409A of the Internal Revenue Code (&#8220;Code&#8221;) applies to any award under this rTSR Program, the award shall be interpreted in a manner consistent with Code section 409A.  Where section 409A applies, in the case of any payment made on termination of employment, a termination of employment shall not be deemed to have occurred unless such termination is also a &#8220;separation from service&#8221; within the meaning of Code section 409A and, for purposes of any such provision, references to a &#8220;termination,&#8221; &#8220;termination of employment,&#8221; or like terms shall mean &#8220;separation from service.&#8221;  Where section 409A applies, in the case of a payment made upon a Change in Control, a Change in Control shall not be deemed to have occurred unless there is a change in the ownership or effective control of Boston Scientific, or in the ownership of a substantial portion of the assets of Boston Scientific, as defined in Code section 409A.  Where required by section 409A in the case of a specified employee (as determined under Code section 409A), payments on termination shall be made on the first business day of the seventh month following termination.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:144pt;width:100%"><div style="padding-left:319.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div><div style="padding-left:319.5pt;text-align:right"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Relative Total Shareholder Return Performance Share Program (&#8220;rTSR Program&#8221;)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Period January 1, 2024 - December 31, 2026</font></div></td></tr></table></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Annual Executive LTIP Program</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">S&#38;P 500 Healthcare Index as of October 11, 2023 &#8211; 65 Companies </font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:4.66pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.679%"><tr><td style="width:1.0%"></td><td style="width:42.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#c5d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company Name</font></td><td colspan="3" style="background-color:#c5d9f1;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company Name</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abbott Laboratories</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Inc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie Inc</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IDEXX Laboratories</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abiomed Inc</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Illumina Inc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agilent Technologies</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte Corp</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Align Technology</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insulet Corporation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen, Inc</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical, Inc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baxter International Inc</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IQVIA Holdings Inc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Becton Dickinson and Company</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Johnson &#38; Johnson</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen Inc</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory Corporation of America Holdings</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bio-Rad Laboratories, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bio-Techne Corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Boston Scientific Corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck &#38; Co., Inc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bristol-Myers Squibb Company</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mettler-Toledo International Inc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderna, Inc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Catalent, Inc</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare, Inc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cencora, Inc</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centene Corp</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quest Diagnostics Incorporated</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles River Laboratories Intl</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals, Inc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Cigna Corp</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ResMed Inc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Cooper Companies</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revvity, Inc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CVS Health Corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">STERIS Corp</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Danaher Corp</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stryker Corporation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Davita Inc</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teleflex Inc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dentsply Sirona Inc</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thermo Fisher Scientific Inc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DexCom Inc</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UnitedHealth Group Inc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edwards Lifesciences Corp</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Universal Health Services, Inc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elevance Health Inc</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex Pharmaceuticals Inc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viatris Inc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GE HealthCare Technologies, Inc</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Waters Corporation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences, Inc</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">West Pharmaceutical Services, Inc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HCA Healthcare, Inc</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zimmer Biomet Holdings, Inc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Henry Schein, Inc</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zoetis Inc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hologic, Inc</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>exhibit103bostonscientific.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1c092b3dffe44164a0f216967ec3a756_1"></div><div style="min-height:154.8pt;width:100%"><div style="padding-left:319.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.3</font></div><div style="padding-left:319.5pt;text-align:right"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Organic Net Sales Growth Performance Share Program</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(&#8220;ONSG Program&#8221;)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Period January 1, 2024 - December 31, 2026</font></div></td></tr></table></div><div><font><br></font></div></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:29.34pt">Purpose of the ONSG Program</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The purpose of the ONSG Program is to align Boston Scientific&#8217;s executive compensation program with the interests of shareholders and to reinforce the concept of pay for performance by providing incentives for the achievement of key business performance objectives which are critical to the success of Boston Scientific.  </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The ONSG Program entails the grant of Restricted Stock Units, and the program shall be administered, under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the &#8220;2011 LTIP&#8221;).  Terms not explicitly defined in this ONSG Program document but defined in the 2011 LTIP shall have the same meaning as in the 2011 LTIP. </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.01pt">Eligible Participants</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The ONSG Program covers members of the Executive Committee on the date that awards are granted under the ONSG Program as determined and, in the amounts, established by the Executive Compensation and Human Resources Committee of the Board of Directors (the &#8220;Committee&#8221;).</font></div><div style="margin-bottom:8pt;margin-top:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">III.&#160;&#160;&#160;&#160;Performance Share Units </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Restricted Stock Units awarded under the ONSG Program (the &#8220;Performance Share Units&#8221;) shall vest only upon satisfaction of both the performance criteria described in this Section III and the payment eligibility criteria described in Section V.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The performance criteria are based on Boston Scientific&#8217;s achievement of the 2024 - 2026 financial plan performance for Organic Net Sales Growth. Organic Net Sales Growth will be measured over a three-year performance period beginning January 1, 2024</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and ending on December 31, 2026. </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The number of Performance Share Units as to which the performance criteria under this ONSG Program shall be determined to have been satisfied will be in a range of 0% to 200% of the target number of Performance Share Units awarded to the participant.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Following the end of the Performance Period, the Committee shall determine the number of Performance Share Units as to which the performance criteria of this ONSG Program have been satisfied, which determination shall be final and binding.  Shares of Common Stock will be delivered or otherwise made available to the participant no later than March 15, 2027 in settlement of the Performance Share Units as to which the performance criteria of this ONSG Program have been satisfied if and to the extent the payment eligibility criteria of Section V below are also satisfied.  Any Performance Share Units as to which the performance criteria of this Section III have not been satisfied shall be forfeited in their entirety.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IV. &#160;&#160;&#160;&#160;Definitions</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8220;Full month&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means 16 or more days </font></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8220;Organic Net Sales Growth (ONSG)&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">excludes from reported net sales the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8220;Partial month&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means less than 16 days</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the three-year period commencing January 1, 2024 and ending on December 31, 2026.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:154.8pt;width:100%"><div style="padding-left:319.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.3</font></div><div style="padding-left:319.5pt;text-align:right"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Organic Net Sales Growth Performance Share Program</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(&#8220;ONSG Program&#8221;)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Period January 1, 2024 - December 31, 2026</font></div></td></tr></table></div><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">V. &#160;&#160;&#160;&#160;Payment Eligibility Criteria</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Except as set forth below with respect to a Change in Control, no Performance Share Units shall vest prior to the end of the Performance Period (December 31, 2026). </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If a participant&#8217;s employment with Boston Scientific and its Affiliates (the &#8220;Company&#8221;) terminates before the last day of the Performance Period, all of his or her Performance Share Units shall be forfeited in their entirety except as set forth below.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participants on military, sick or other bona fide leave of absence on December 31, 2026 will not be deemed to have terminated employment with the Company if such absence does not exceed 180 days or, if longer, the period the participant retains the right by statute or by contract to return to employment with the Company. </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to the terms of any separate Change in Control or similar agreement to which a participant is bound, if there is a Change in Control after December 31, 2024 but before the end of the Performance Period, shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this ONSG Program have been satisfied using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2026, as determined by the Committee immediately prior to the consummation of the Change in Control.  Such issuance shall occur within 70 days of the effective date of the Change in Control, on a prorated basis.  The number of shares to be issued on a prorated basis shall be determined as follows&#58; (# Performance Share Units achieved pursuant to the table in Section III * ((# of full and partial months during the Performance Period, rounded up to the nearest whole month&#47;36)).  The number of prorated shares to be issued to the participant, if any, will be approved by the Committee at its next regular meeting.  In the event a Change in Control occurs prior to January 1, 2025, the Performance Share Units will be forfeited in their entirety.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If a participant&#8217;s employment with the Company terminates due to Retirement after December 31, 2024 but before the end of the Performance Period, the participant will continue to be eligible to vest in a prorated number of Performance Share Units and shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this ONSG Program have been satisfied at the end of the Performance Period, but no later than March 15, 2027, on a prorated basis using the effective date of the participant&#8217;s termination of employment. The number of shares to be issued on a prorated basis shall be determined as follows&#58; (# Performance Share Units achieved pursuant to the table in Section III * ((# of full and partial months worked during the Performance Period, rounded up to nearest whole month) &#47; 36)).  The number of prorated shares, if any, to be issued to the participant will be approved by the Committee at its regular meeting next following the date of the participant&#8217;s employment termination. In the event a participant&#8217;s employment with the Company terminates due to Retirement prior to January 1, 2025, the Performance Share Units will be forfeited in their entirety.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If a participant&#8217;s employment with the Company terminates due to death or Disability before the end of the Performance Period, the participant will continue to be eligible to vest in all of his or her Performance Share Units and shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this ONSG Program have been satisfied at the end of the Performance Period, but no later than March 15, 2027. The number of shares, if any, to be issued to the participant will be approved by the Committee at its regular meeting next following the date of the participant&#8217;s employment termination.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VI. &#160;&#160;&#160;&#160;Termination, Suspension or Modification and Interpretation of the ONSG </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Program</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:154.8pt;width:100%"><div style="padding-left:319.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.3</font></div><div style="padding-left:319.5pt;text-align:right"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Organic Net Sales Growth Performance Share Program</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(&#8220;ONSG Program&#8221;)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Period January 1, 2024 - December 31, 2026</font></div></td></tr></table></div><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Committee has sole authority over administration and interpretation of the ONSG Program.&#160; The Committee hopes and expects to continue the ONSG Program in effect but retains its right to exercise discretion as it sees fit, including to prospectively terminate, suspend or modify the ONSG program or criteria for eligible participation in future years.&#160; If suspended, the Committee may reinstate with or without modification all or part of the ONSG Program or criteria for eligible participation. However, no amendment of the ONSG Program after the grant date may materially and adversely impair a participant&#8217;s rights under awards made pursuant to the ONSG Program without the participant&#8217;s consent unless the amendment is necessary or desirable to facilitate compliance with applicable law, as determined in the sole discretion of the Committee. The Committee reserves the exclusive right to determine eligibility to participate in this ONSG Program and to interpret all applicable terms and conditions.</font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VII. &#160;&#160;&#160;&#160;Recoupment Policy</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">General Recoupment Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  To the extent permitted by governing law, the Board, in its discretion, may seek Recovery of Performance Share Units granted to a Current Executive Committee Member or Former Executive Committee Member if, in the judgment of the Board, such Executive Committee Member, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">while serving in capacity as a Current Executive Committee Member,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> commits misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The following terms shall have the meaning set forth below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;&#34;Current Executive Committee Member&#34; means any individual currently designated as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">a corporate officer of the Company who is in an organizational job level of E-4 or E-5 (or any equivalent level under any future organizational framework</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;&#34;Executive Committee Member&#34; means any Current Executive Committee Member or Former Executive Committee Member.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-108pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;&#34;Former Executive Officer&#34; means any individual previously (but not currently) designated as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">a corporate officer of the Company who was in an organizational job level of E-4 or E-5 (or any equivalent level under any future organizational framework)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;&#34;Recovery&#34; means the forfeiture or cancellation of unvested Performance Share Units.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Recoupment Required by Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Performance Share Units and any compensation associated therewith are subject to forfeiture, recovery by the Company or other action pursuant to any compensation recovery policy adopted by the Board or the Committee in effect from time to time, which includes but is not limited to the Company&#8217;s Dodd-Frank Clawback Policy and any other compensation recovery policy adopted by the Board or the Committee including in response to the requirements of Section 10D of the Securities Exchange Act of 1934, as amended, the U.S. Securities and Exchange Commission&#8217;s final rules thereunder, and any applicable listing rules or other rules and regulations implementing the foregoing or as otherwise required by law.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIII. &#160;&#160;&#160;&#160;Other</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This document sets forth the terms of the ONSG Program and is not intended to be a contract or employment agreement between the participant and the Company.  As applicable, it is understood that both the participant and the Company have the right to terminate the participant&#8217;s employment with the Company at any time, with or without cause and with or without notice, in acknowledgement of the fact that their employment relationship is &#8220;at will.&#8221; </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To the extent section 409A of the Internal Revenue Code (&#8220;Code&#8221;) applies to any award under this ONSG Program, the award shall be interpreted in a manner consistent with Code section 409A.  Where section 409A applies, in the case of any payment made on termination of employment, a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:154.8pt;width:100%"><div style="padding-left:319.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.3</font></div><div style="padding-left:319.5pt;text-align:right"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Organic Net Sales Growth Performance Share Program</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(&#8220;ONSG Program&#8221;)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Period January 1, 2024 - December 31, 2026</font></div></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">termination of employment shall not be deemed to have occurred unless such termination is also a &#8220;separation from service&#8221; within the meaning of Code section 409A and, for purposes of any such provision, references to a &#8220;termination,&#8221; &#8220;termination of employment,&#8221; or like terms shall mean &#8220;separation from service.&#8221;  Where section 409A applies, in the case of a payment made upon a Change in Control, a Change in Control shall not be deemed to have occurred unless there is a change in the ownership or effective control of Boston Scientific, or in the ownership of a substantial portion of the assets of Boston Scientific, as defined in Code section 409A.  Where required by section 409A in the case of a specified employee (as determined under Code section&#160;409A), payments on termination shall be made on the first business day of the seventh month following termination.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>bsx-20231116.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:accfbc9b-b6f9-42e2-86a3-003f44f15930,g:e3ca2334-d848-4fe8-9ce5-a9f46e6577dc-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bsx="http://www.bostonscientific.com/20231116" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bostonscientific.com/20231116">
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bsx-20231116_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bsx-20231116_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bsx-20231116_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverDocument" roleURI="http://www.bostonscientific.com/role/CoverDocument">
        <link:definition>0000001 - Document - Cover Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bsx_SeniorNotedue2027Member" abstract="true" name="SeniorNotedue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>bsx-20231116_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:accfbc9b-b6f9-42e2-86a3-003f44f15930,g:e3ca2334-d848-4fe8-9ce5-a9f46e6577dc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/CoverDocument" xlink:type="simple" xlink:href="bsx-20231116.xsd#CoverDocument"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/CoverDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c75f431a-038e-4352-b502-515c6a09f3df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_DocumentType_c75f431a-038e-4352-b502-515c6a09f3df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ef675d78-66d8-4b03-a704-38bab5a64d66" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_DocumentPeriodEndDate_ef675d78-66d8-4b03-a704-38bab5a64d66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d4f91ecf-6739-4c24-aa3b-eeb51fd5f6ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_EntityRegistrantName_d4f91ecf-6739-4c24-aa3b-eeb51fd5f6ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_75d212a0-f11d-4821-8a59-9094550aa059" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_AmendmentFlag_75d212a0-f11d-4821-8a59-9094550aa059" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2ccf65a4-bf26-4e43-a466-d1ed964a9dda" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2ccf65a4-bf26-4e43-a466-d1ed964a9dda" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_58cb2874-78cf-4e91-9624-4c91b50d7f1c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_EntityFileNumber_58cb2874-78cf-4e91-9624-4c91b50d7f1c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_aa4dcb11-e7c3-40b0-8485-f7683ef5677f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_EntityTaxIdentificationNumber_aa4dcb11-e7c3-40b0-8485-f7683ef5677f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a51d1286-1bd8-4780-b985-52a296311df5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_EntityAddressAddressLine1_a51d1286-1bd8-4780-b985-52a296311df5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e89d3f10-a9a8-422b-8ee8-45c6a85bf393" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_EntityAddressCityOrTown_e89d3f10-a9a8-422b-8ee8-45c6a85bf393" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_85252998-7b31-4dc2-8321-2c24579ea3d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_EntityAddressStateOrProvince_85252998-7b31-4dc2-8321-2c24579ea3d9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ec9d701f-614e-4f5f-a6c1-f6835c462cc2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_EntityAddressPostalZipCode_ec9d701f-614e-4f5f-a6c1-f6835c462cc2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2322dbb0-8f97-4d3e-9a7b-443d78f48aa3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_CityAreaCode_2322dbb0-8f97-4d3e-9a7b-443d78f48aa3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0b7a2faa-42e1-4cc7-994e-f5ccfc008e0d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_LocalPhoneNumber_0b7a2faa-42e1-4cc7-994e-f5ccfc008e0d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_d1c23979-0167-41f2-89ee-83375209dc6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_WrittenCommunications_d1c23979-0167-41f2-89ee-83375209dc6f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_3faf883f-3d67-422b-a93e-6c032093a430" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_SolicitingMaterial_3faf883f-3d67-422b-a93e-6c032093a430" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_99b6c868-df86-4a85-8cca-ee66361e0641" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_PreCommencementTenderOffer_99b6c868-df86-4a85-8cca-ee66361e0641" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_a6a91d77-3299-4016-af02-8d4ea8fb9be2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_a6a91d77-3299-4016-af02-8d4ea8fb9be2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3a997cdd-279b-4d7c-b92f-8d5b895cb480" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_Security12bTitle_3a997cdd-279b-4d7c-b92f-8d5b895cb480" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c3a36625-e44c-4f06-94c7-59aecb6cc369" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_TradingSymbol_c3a36625-e44c-4f06-94c7-59aecb6cc369" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5e0ba7dc-a51d-4a18-b0e6-5990a7b350f9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_SecurityExchangeName_5e0ba7dc-a51d-4a18-b0e6-5990a7b350f9" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3af2f648-9e6f-44f9-a91e-72464e0ee2dd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_EntityEmergingGrowthCompany_3af2f648-9e6f-44f9-a91e-72464e0ee2dd" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_47421fd0-1688-4dc4-9f46-fc7a3541b3d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_EntityCentralIndexKey_47421fd0-1688-4dc4-9f46-fc7a3541b3d3" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_fcbe5d80-fcaa-4c48-a00e-a341e3ea397d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_EntitiesTable_fcbe5d80-fcaa-4c48-a00e-a341e3ea397d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_36468b9a-3ccd-480f-b572-d9e75aefb447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_fcbe5d80-fcaa-4c48-a00e-a341e3ea397d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_36468b9a-3ccd-480f-b572-d9e75aefb447" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_36468b9a-3ccd-480f-b572-d9e75aefb447_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_36468b9a-3ccd-480f-b572-d9e75aefb447" xlink:to="loc_us-gaap_ClassOfStockDomain_36468b9a-3ccd-480f-b572-d9e75aefb447_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_97058c68-14cc-4737-a631-d7531309d651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_36468b9a-3ccd-480f-b572-d9e75aefb447" xlink:to="loc_us-gaap_ClassOfStockDomain_97058c68-14cc-4737-a631-d7531309d651" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_83a63868-5583-466c-b8be-8ff4ba0a153e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_97058c68-14cc-4737-a631-d7531309d651" xlink:to="loc_us-gaap_CommonStockMember_83a63868-5583-466c-b8be-8ff4ba0a153e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SeniorNotedue2027Member_f39f245c-0fff-4251-b221-7d0724b02338" xlink:href="bsx-20231116.xsd#bsx_SeniorNotedue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_97058c68-14cc-4737-a631-d7531309d651" xlink:to="loc_bsx_SeniorNotedue2027Member_f39f245c-0fff-4251-b221-7d0724b02338" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>bsx-20231116_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:accfbc9b-b6f9-42e2-86a3-003f44f15930,g:e3ca2334-d848-4fe8-9ce5-a9f46e6577dc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_ee1771af-5314-4c5c-964e-9c78c3e84d6c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c636e171-c086-41a4-ad62-e73d2614f548_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b3effc17-98ba-43fd-ba37-e4aba9f541c4_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3aab0302-3148-4263-8327-07198aa0253e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_fdbc96b5-ba64-4475-a208-ae210f6799ef_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_aad61ba4-114b-4331-9410-2579169b7706_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_684b9b6f-d30f-4815-bd8f-59622ad4237b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_923d73e9-9bb3-4e52-9df0-00a21e2f48be_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_488ba225-d74b-4701-a3f5-5dd38dd1e4d2_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_58508e17-ae66-4ec0-a557-d14426cfc7e3_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_d16a5b7a-79e5-4573-8b1b-3691324e2cf8_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_bedb6cb5-7fa5-4149-a971-283f8da2fad6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_SeniorNotedue2027Member_c4b9cd1b-6360-4810-b03b-9059b735a383_terseLabel_en-US" xlink:label="lab_bsx_SeniorNotedue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Note due 2027 [Member]</link:label>
    <link:label id="lab_bsx_SeniorNotedue2027Member_label_en-US" xlink:label="lab_bsx_SeniorNotedue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Note due 2027 [Member]</link:label>
    <link:label id="lab_bsx_SeniorNotedue2027Member_documentation_en-US" xlink:label="lab_bsx_SeniorNotedue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Note due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SeniorNotedue2027Member" xlink:href="bsx-20231116.xsd#bsx_SeniorNotedue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_SeniorNotedue2027Member" xlink:to="lab_bsx_SeniorNotedue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_ec1e98c7-9847-4a89-8f31-a6719403f10c_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3e752922-1067-4cfc-a4fc-c4389b5733da_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_cbfa1c5e-22e5-4a9b-a5fa-eda2ab9f55f5_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a495ac07-a151-4253-89e6-0eb953f734ea_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_4adc3bf0-0d3e-4dc4-add0-2f2da53d86a3_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_90a84f65-ce6c-4f28-968b-34b891e92d9b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_817c38c3-254d-4979-a9bb-70e6fe0f955c_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_19cda9fc-3c90-46f4-9fa7-27df9ec5d41f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_6ec0955d-ff9a-4a77-9f1f-7290216c7b2e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_aa13cde9-2c24-4c08-be90-1cb2e69b9629_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_eed69ab0-e10b-4f29-949a-8f69fdd488be_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_9df38e39-5945-48cb-9c68-b4f9d594c840_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_702d3aef-c5a5-49bf-a344-62da3522e8a8_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f6234c31-14a7-4b20-8898-d5807eba1e6d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_fbddd649-28b4-4b6a-90c7-f85bf26d5e55_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_5c9ce2b8-5bf4-41bc-9fa3-f31712404f2f_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>bsx-20231116_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:accfbc9b-b6f9-42e2-86a3-003f44f15930,g:e3ca2334-d848-4fe8-9ce5-a9f46e6577dc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bostonscientific.com/role/CoverDocument" xlink:type="simple" xlink:href="bsx-20231116.xsd#CoverDocument"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/CoverDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b5c42028-d7e8-4261-af08-d76602559c57" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_fcbe5d80-fcaa-4c48-a00e-a341e3ea397d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b5c42028-d7e8-4261-af08-d76602559c57" xlink:to="loc_dei_EntitiesTable_fcbe5d80-fcaa-4c48-a00e-a341e3ea397d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_36468b9a-3ccd-480f-b572-d9e75aefb447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_fcbe5d80-fcaa-4c48-a00e-a341e3ea397d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_36468b9a-3ccd-480f-b572-d9e75aefb447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_97058c68-14cc-4737-a631-d7531309d651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_36468b9a-3ccd-480f-b572-d9e75aefb447" xlink:to="loc_us-gaap_ClassOfStockDomain_97058c68-14cc-4737-a631-d7531309d651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_83a63868-5583-466c-b8be-8ff4ba0a153e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_97058c68-14cc-4737-a631-d7531309d651" xlink:to="loc_us-gaap_CommonStockMember_83a63868-5583-466c-b8be-8ff4ba0a153e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SeniorNotedue2027Member_f39f245c-0fff-4251-b221-7d0724b02338" xlink:href="bsx-20231116.xsd#bsx_SeniorNotedue2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_97058c68-14cc-4737-a631-d7531309d651" xlink:to="loc_bsx_SeniorNotedue2027Member_f39f245c-0fff-4251-b221-7d0724b02338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_fcbe5d80-fcaa-4c48-a00e-a341e3ea397d" xlink:to="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c75f431a-038e-4352-b502-515c6a09f3df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_DocumentType_c75f431a-038e-4352-b502-515c6a09f3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ef675d78-66d8-4b03-a704-38bab5a64d66" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_DocumentPeriodEndDate_ef675d78-66d8-4b03-a704-38bab5a64d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d4f91ecf-6739-4c24-aa3b-eeb51fd5f6ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_EntityRegistrantName_d4f91ecf-6739-4c24-aa3b-eeb51fd5f6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_75d212a0-f11d-4821-8a59-9094550aa059" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_AmendmentFlag_75d212a0-f11d-4821-8a59-9094550aa059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2ccf65a4-bf26-4e43-a466-d1ed964a9dda" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2ccf65a4-bf26-4e43-a466-d1ed964a9dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_58cb2874-78cf-4e91-9624-4c91b50d7f1c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_EntityFileNumber_58cb2874-78cf-4e91-9624-4c91b50d7f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_aa4dcb11-e7c3-40b0-8485-f7683ef5677f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_EntityTaxIdentificationNumber_aa4dcb11-e7c3-40b0-8485-f7683ef5677f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a51d1286-1bd8-4780-b985-52a296311df5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_EntityAddressAddressLine1_a51d1286-1bd8-4780-b985-52a296311df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e89d3f10-a9a8-422b-8ee8-45c6a85bf393" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_EntityAddressCityOrTown_e89d3f10-a9a8-422b-8ee8-45c6a85bf393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_85252998-7b31-4dc2-8321-2c24579ea3d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_EntityAddressStateOrProvince_85252998-7b31-4dc2-8321-2c24579ea3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ec9d701f-614e-4f5f-a6c1-f6835c462cc2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_EntityAddressPostalZipCode_ec9d701f-614e-4f5f-a6c1-f6835c462cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2322dbb0-8f97-4d3e-9a7b-443d78f48aa3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_CityAreaCode_2322dbb0-8f97-4d3e-9a7b-443d78f48aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0b7a2faa-42e1-4cc7-994e-f5ccfc008e0d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_LocalPhoneNumber_0b7a2faa-42e1-4cc7-994e-f5ccfc008e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_d1c23979-0167-41f2-89ee-83375209dc6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_WrittenCommunications_d1c23979-0167-41f2-89ee-83375209dc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_3faf883f-3d67-422b-a93e-6c032093a430" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_SolicitingMaterial_3faf883f-3d67-422b-a93e-6c032093a430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_99b6c868-df86-4a85-8cca-ee66361e0641" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_PreCommencementTenderOffer_99b6c868-df86-4a85-8cca-ee66361e0641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_a6a91d77-3299-4016-af02-8d4ea8fb9be2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_a6a91d77-3299-4016-af02-8d4ea8fb9be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3a997cdd-279b-4d7c-b92f-8d5b895cb480" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_Security12bTitle_3a997cdd-279b-4d7c-b92f-8d5b895cb480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c3a36625-e44c-4f06-94c7-59aecb6cc369" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_TradingSymbol_c3a36625-e44c-4f06-94c7-59aecb6cc369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5e0ba7dc-a51d-4a18-b0e6-5990a7b350f9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_SecurityExchangeName_5e0ba7dc-a51d-4a18-b0e6-5990a7b350f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3af2f648-9e6f-44f9-a91e-72464e0ee2dd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_EntityEmergingGrowthCompany_3af2f648-9e6f-44f9-a91e-72464e0ee2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_47421fd0-1688-4dc4-9f46-fc7a3541b3d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_bd9cddd7-9799-4c3f-85aa-d1b094b015b3" xlink:to="loc_dei_EntityCentralIndexKey_47421fd0-1688-4dc4-9f46-fc7a3541b3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" $* O,# 2(  A$! Q$!_\0
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MBB@ HHHH **** "BBB@ HHHH \B_;?\ VPOAS^PC^SOK7[3'Q8T/7-2T+03
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ML\"2@#\'KHZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;A8HP3T&YB!S7XD_\&=UU<->_'C3UF80R1>'Y'3U93? 'UX#-^=?I)_P5O\
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M1SQGKZ>]% ']1O\ P;AZ.=)_X)*_#R8[/]-N]3N!L7'6\D7GU/R5]UU\2?\
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M/_:U?TK/]TU_-3_P=0_\I3)O^R?:1_[6H _-ZOTT_P"#3[_E)YJO_9*M5_\
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MRH 6BF^9[4!P>Q_&@!U%(IR,XI: "BBB@ HHHH **** "BBB@ HHHH ****
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M.V7_ %]Q_P#H0K^TCX,?\D>\)_\ 8M6'_I.E '2T444 %1SR;"H]34E>"_\
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M\'>%?'6@7GA3QGX>L]5TS4(##?:?J%LLT,\9&"K(P(8?6OR:_P"#D+_@IO\
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M4/'4TY0D@^7%:/DX^KJ/QH _ "M+P9H%QXK\7Z7X7M8R\FI:A#:HJYR3)(J
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MX.& !_5!161X+\7Z+X]\-Z=XT\*ZM#?:5JUC%=Z?>0-E)H9%#(ZGCJ"#6O0
M4444 %%%% !1110 4444 %%%% !1110 CG"$X[5^;G_!P+_P5XN?V"?@^GP'
M^!OB&*/XI^-+%_(ND*N^@Z>Q*M=[3P)6^81Y& 06P0H%?H7\0?&_A_X;^ ]9
M^(/BJ[%OIFAZ7/?W\QQ\D,49D8\^RFOX_/V[?VKO&/[;/[6/C7]I3QG<,TWB
M+6)7T^U+DK96*?);VZ?[*1*J^Y!)Y)) .;^#GPD^,7[6WQTTGX5_#O3KSQ#X
MP\8:OY4)GF9Y)II&)>:61LX &YV<] "<U_4#_P $M?\ @D'^SY_P32^&ELFA
M:)::[\0;^V4^)O'%S;9FF<\F&WW9\B!3T5<%OO-D]/@S_@TH_8KT>3PSXW_;
ML\6:4)+YM2;PSX2,Z ^3&D<<MW.N><L9(H@1_<D%?MB@VK@T "CY1N'..:6B
MB@ P/2H+ZTAOH'L[F!)8I4*2QR(&5E(P00>",=C4]% 'Y3_\%@/^#=/X3_M+
M:1JWQ\_8N\*6?A+XAPV[7-_X<L_W.G>(7&6.U"0EO<$<!EVHQQN&<M7\]_BS
MPCXI\!>);[P5XX\.WFDZOIET]MJ6F:A;-#-;3(=KQNC %6!!!!%?VSD9K\>?
M^#FG_@E#I?Q*^'UQ_P % O@9X>6/Q-X=B"^/["TBQ_:5@!A;S _Y:P]&/\4;
M=1L^8 _ ]Y'E<R2.68G)9CDDU^QO_!GS_P EX^,/_8I6/_I57XX@@]*_8[_@
MSY_Y+Q\8?^Q2L?\ TJH _>JBL3XA?$GP#\)O"EWXZ^)OC#3M!T6Q4->ZKJMV
MD%O "0H+NY 7)('->6?\/*_^"?'_ $>G\,O_  LK3_XY0!^3/_!XK_R/_P !
M_P#L#>(?_1UA7XMU^M__  =:?M'? /\ :$\<?!6Z^!?QC\-^+HM+TK7$U*3P
M[K$-V+5I);(H)#&QVE@K8!ZX-?DA0!;T#_D.V7_7W'_Z$*_M(^#'_)'O"?\
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M+_P37^/W_!27XSP_#7X1:4]IHUI-&WBCQ;<6[/::/ Q/SL1@/(P!VQ@Y8CL
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M/N-R1@D@ _HEHJAX;\4^&_&6B6OB;PEKMIJ>FWT"S6>H6%PLT,\;#*NCJ2K
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M37] %O#;Z?&D*1A$"A(T0<*!T4#T% $T2[5P?6O(/^"@W_)C7Q?_ .R<:O\
M^DDM7[W]N7]BC3;R;3M2_; ^%MO<6\K13V\_Q TU'C=3AE93-D$$$$'D$5Y!
M^W9^VW^QGXC_ &,OBMX>\/?M:_#._O[WP!JD%G967CS3I99Y6M9 J(BS%F8D
M@  9)Z4 ?R<4AZ?C2TA^H_$T ?U<?\$$O^437P>_[ 4O_I1+7V#7Y]?\$0OV
MO?V3?AY_P2]^%'@[Q_\ M0?#O0M7LM%D2\TO6/&MA:W,#&XD(#Q22JRG!!Y
MZU]<:)^VM^QOXFUJT\-^&?VLOAIJ6HWTZP65AI_CK3YIKB5CA41$F+.Q/  !
M)H ]-H/3\:IZSXAT3P[I5UKNOZK;V-C8V[SWMY=S+'%;Q("SR.[$!$5026)
M !S7FC_MX_L.*I8_MF?"C Y/_%Q-,_\ C] '\Z/_  <H?\I:/''_ &"=*_\
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MZ?#B0?\ M_7[GT4 ?AA_Q!S>-,8/[?NF?^&XD_\ D^C_ (@Y?&?_ $?YI?\
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M-N21[<O(92" =KL5R.0:_3]HE8DL3_A3J &)#Y;9#<>E/HHH **** "BBB@
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M&0#C/- !12%E'4T;U)P&Z4 +12;USC<*4$'H: "BBB@ HHHH **** "BD,B
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M.!,--SD%I68'LB]_N#P__P $]?V&_"NE_P!B:!^R;\/[:T P(4\+6Q 'XJ:
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M_P#P3-'/_#?OP?\ _#AZ=_\ 'J_+S_B#NNCS_P -S)_X0Y_^2J^8_P#@J_\
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M/5_^"9H_YO\ ?@__ .'#T_\ ^.U^4W_$'M\17./^&T=%!'_4K3?_ !VOD?\
MX*U?\$3/$W_!*SP%X2\<Z_\ '6P\7)XJU:XLDM[327MC 8HUD+$L[;L[L8H
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M-#Q6=0']B'PH;G[-]EU"YL_]9YZ[MWV??]T8W8YQF@#]LO\ AZM_P3-_Z/\
M?@__ .'#T_\ ^.TO_#U;_@F;_P!'^_![_P .'I__ ,>K\N_^(.ZZ_P"CYX__
M  AS_P#)5+_Q!W77_1\T?_A#G_Y*H _4/_AZM_P3-_Z/]^#W_AP]/_\ CU'_
M  ]6_P""9O\ T?[\'O\ PX>G_P#QZOR\_P"(.ZZ_Z/FC_P#"'/\ \E5\V_\
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MQYX"TQ=&\(_LO^ K*V10%B3PI:L !T^\AH _(#X7?\'@'BI+V*/XS?L=6,L
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M:<\::*C>./BC;B]2::,;]/TC)^S0*><&0#SF/'WT'\-?SW_LX_"ZZ^-WQ_\
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M?]$R^('_ (+8/_CM=9_Q"R_\$M_^@5XW_P#"KD_^)H_XA9?^"6__ $"O&_\
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MO_DSGX3?]DST'_TW05Z97F'[%#A_V.?A,58,I^&>@[6'<?V?!@UZ?0 4444
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MOC7IO[&?PE\1K>^'?A[>23^)KJTDW0W6LD%#$".'$",RYZ!W<=0:_/O]B/\
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MBVT#PM=64^R:*>=]TTJ$<J4MXYV!'1@OK7S)_P &MOQ,_:M_:(\'?%#XV_M
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M^NJ@ K\K?^#L3]FV[^)G[#WAGX_:%8M)=?#GQ8@U!DCR5T^^7R7?C^[.EM]
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M=X\<>(_$43+B2!94'V:W?/(9(=I*_P +NX[4 ?<4+'RER&/'4BBE0,J@9HH
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M#7]3N-;UWX.6=[>W4K2W5W=^,+:269R<EF=G)8D]23F@#X% R<"OU._X-)V
M_P""@WB[&#_Q;&ZS@]/],M:\C_XAL/\ @K7_ -$)TO\ \*FT_P#BZV_ O_!O
MY_P6R^%VK2:_\,O!,_AR^EA,,MYH/C^*SE>,D'87BE4E<@'&<<"@#^FK</\
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M8D  DBOY<?@3_P %Y?\ @J/^SWX+MOA]X)_:2N+_ $NSA$-G'XBTRWU%X(P
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M4#9_X)?S+C_F=]+YS_MM7YY>(?\ @D%_P<+7OB._NM+\:>,A!+=R/"J_&"4
M(6)&!]HXXQQ7.>-O^"&W_!>GXEZ,?#GQ'CUWQ!IQD60V&M_$\7<.]>C;)9V7
M(['&10!^;H&!C/;L:*^\O^(;#_@K5V^!.E_^%3:?_%T?\0V'_!6O_HA.E_\
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M44 )Y: 8VC%9OBCP5X.\<:3+H/C3PIINKV,Z[9K+5+&.XBD'HR2 @_B*TZ*
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7ZK"B@UU(10=P%+10 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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12]+8.9L     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140703322832960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Document<br></strong></div></th>
<th class="th"><div>Nov. 16, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 16,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BOSTON SCIENTIFIC CORPORATION<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-2695240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">300 Boston Scientific Way<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Marlborough<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">01752-1234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">683-4000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000885725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BSX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bsx_SeniorNotedue2027Member', window );">Senior Note due 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.625% Senior Notes due 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BSX27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bsx_SeniorNotedue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bsx_SeniorNotedue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>bsx-20231116_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bsx="http://www.bostonscientific.com/20231116"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bsx-20231116.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
        </entity>
        <period>
            <startDate>2023-11-16</startDate>
            <endDate>2023-11-16</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-16</startDate>
            <endDate>2023-11-16</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:SeniorNotedue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-16</startDate>
            <endDate>2023-11-16</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-24">0000885725</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-25">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-11-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">BOSTON SCIENTIFIC CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">1-11083</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">04-2695240</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">300 Boston Scientific Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Marlborough</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">01752-1234</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">508</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">683-4000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-17">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="c-2" id="f-18">Common Stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-19">BSX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-20">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-21">0.625% Senior Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-22">BSX27</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-23">NYSE</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MD=&+MV%RS<\^TY0(3?Z88SMRFEL%+;$*+@5L@28*MD(^)!X>WMIXRZ!Z;UV
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( 'R =E=>FV=#[0   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( 'R =E>97)PC$ 8  )PG   3
M      "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ?(!V
M5\LKJ!S?!   *14  !@              ("!# @  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( 'R =E>?H!OPL0(  .(,   -
M      "  2$-  !X;"]S='EL97,N>&UL4$L! A0#%     @ ?(!V5Y>*NQS
M    $P(   L              ( !_0\  %]R96QS+RYR96QS4$L! A0#%
M  @ ?(!V5S?4:_XV 0  *P(   \              ( !YA   'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( 'R =E<D'INBK0   /@!   :
M  "  4D2  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M 'R =E=ED'F2&0$  ,\#   3              "  2X3  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     )  D /@(  '@4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="bsx-20231116.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/CoverDocument</Role>
      <ShortName>Cover Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="bsx-20231116.htm">bsx-20231116.htm</File>
    <File>bsx-20231116.xsd</File>
    <File>bsx-20231116_def.xml</File>
    <File>bsx-20231116_lab.xml</File>
    <File>bsx-20231116_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "bsx-20231116.htm": {
   "nsprefix": "bsx",
   "nsuri": "http://www.bostonscientific.com/20231116",
   "dts": {
    "inline": {
     "local": [
      "bsx-20231116.htm"
     ]
    },
    "schema": {
     "local": [
      "bsx-20231116.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "bsx-20231116_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "bsx-20231116_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bsx-20231116_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 1,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2022": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 25
   },
   "report": {
    "R1": {
     "role": "http://www.bostonscientific.com/role/CoverDocument",
     "longName": "0000001 - Document - Cover Document",
     "shortName": "Cover Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bsx-20231116.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bsx-20231116.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover page.",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentType",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entities [Table]",
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "bsx_SeniorNotedue2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bostonscientific.com/20231116",
     "localname": "SeniorNotedue2027Member",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Note due 2027 [Member]",
        "label": "Senior Note due 2027 [Member]",
        "documentation": "Senior Note due 2027 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0000885725-23-000051-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000885725-23-000051-xbrl.zip
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MFNL':U:-JK7O@-8W"\2S6H<TV)>GK&*#[9HM*Q;3; :,C#+QOE MQ!5FU''
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M?3/$^\BBT,M#WYG#?Y-@ZI[_/U!+ P04    " !\@'97I!>P12T#  #9"@
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M6<#],I25HB&,GQB?#60UYFI;3._QSB]02P,$%     @ ?(!V5RG_W$%I"
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M*!6Q4/,9)TYG@G#CG9=.B:C4)!RLF-WP@O#/ /%T8;=BT_@$9T5?O5?=![>
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MSPJ<9PH, YBK4-=QBM'C:2/>5$L#8F4_934 3.OY5$B^&AA)FW'23*J7F%[
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M;P:11_T&D9]&*EG _Z;%+'OZ_U!+ P04    " !\@'97>HU"SW@;   ;]0
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M9^TCUMS_@B1?2X#V"-=U;>2DI54%[*P!&">\SX(4D'D,;'$QQ&\>!TZ3DZT
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MC_Y;2B/KH3%&^*RTI?8QPDJPH%R"?U.,[Y'PY2Q!2O36)6P$PYI<T]35BD_
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M+FAT;5!+ 0(4 Q0    ( 'R =E>D%[!%+0,  -D*   0              "
M 8T<  !B<W@M,C R,S$Q,38N>'-D4$L! A0#%     @ ?(!V5RG_W$%I"
M(#P  !0              ( !Z!\  &)S>"TR,#(S,3$Q-E]D968N>&UL4$L!
M A0#%     @ ?(!V5Q\+0._F#   >78  !0              ( !@R@  &)S
M>"TR,#(S,3$Q-E]L86(N>&UL4$L! A0#%     @ ?(!V5XK-&&P2"   NSX
M !0              ( !FS4  &)S>"TR,#(S,3$Q-E]P<F4N>&UL4$L! A0#
M%     @ ?(!V5U6D6/9))0  =1P! !X              ( !WST  &5X:&EB
M:70Q,#%B;W-T;VYS8VEE;G1I9FEC+FAT;5!+ 0(4 Q0    ( 'R =E=ZC4+/
M>!L  !OU   >              "  61C  !E>&AI8FET,3 R8F]S=&]N<V-I
M96YT:69I8RYH=&U02P$"% ,4    " !\@'97" MJ OX1   V<0  '@
M        @ $8?P  97AH:6)I=#$P,V)O<W1O;G-C:65N=&EF:6,N:'1M4$L%
3!@     (  @ )@(  %*1      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
